Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dermatomyositis.

J P Callen

    Disease-A-Month : DM
    |May 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Dermatomyositis and polymyositis are autoimmune disorders potentially linked to cancer. While skin issues can be stubborn, systemic symptoms may improve with corticosteroids or immunosuppressants.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Anti-C1q antibodies in systemic lupus erythematosus.

    Lupus·2014
    Same author

    Hypertrophic lupus erythematosus complicating long-standing systemic lupus erythematosus.

    Lupus·2011
    Same author

    Drug-induced subacute cutaneous lupus erythematosus.

    Lupus·2010
    Same author

    Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus.

    Lupus·2004
    Same author

    Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis.

    Clinical and experimental dermatology·2004
    Same author

    Update on the management of cutaneous lupus erythematosus.

    The British journal of dermatology·2004
    Same journal

    Disturbances due to cold.

    Disease-a-month : DM·2026
    Same journal

    GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review.

    Disease-a-month : DM·2026
    Same journal

    GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.

    Disease-a-month : DM·2026
    Same journal

    Periodontal disease and diabetic kidney disease: A comprehensive analysis.

    Disease-a-month : DM·2026
    Same journal

    Foreword for Glucagon-like peptide-1 receptor agonists (GLP-1) and its promise for potential benefits.

    Disease-a-month : DM·2026
    Same journal

    Foreword for insulin autoimmune syndrome (Hirata Disease): An updated review of epidemiology, pathophysiology, clinical features, diagnosis, and management.

    Disease-a-month : DM·2026
    See all related articles

    Area of Science:

    • Rheumatology
    • Immunology
    • Dermatology

    Background:

    • Dermatomyositis and polymyositis are idiopathic inflammatory myopathies.
    • These conditions can overlap with other connective tissue diseases.
    • Malignancy is a known association with dermatomyositis and polymyositis.

    Purpose of the Study:

    • To outline the clinical features of adult and juvenile dermatomyositis and polymyositis.
    • To describe visceral manifestations of these disorders.
    • To review diagnostic aids and treatment strategies.

    Main Methods:

    • Clinical feature analysis of adult and juvenile dermatomyositis and polymyositis.
    • Review of visceral manifestations.
    • Evaluation of diagnostic tools including enzymatic, electromyographic, and histologic findings.

    Related Experiment Videos

  • Assessment of treatment responses.

    • Main Results:

    • Cutaneous lesions in dermatomyositis and polymyositis can be treatment-resistant.
    • Systemic manifestations often respond to corticosteroid or immunosuppressive therapy.
    • Prognosis is significantly impacted by treatment in non-malignant cases.

    Conclusions:

    • Dermatomyositis and polymyositis require a comprehensive diagnostic approach.
    • Treatment strategies, including corticosteroids and immunosuppressants, can alter patient outcomes.
    • The association with malignancy necessitates careful monitoring and management.